Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
SUVR using the whole cerebellum as the reference region and centiloid (CL) cutoffs for early and established amyloid pathology were 1.10 (13.5 CL) and 1.24 (35.7 CL), respectively.
-
Amyloid-PET presented higher diagnostic accuracy, sensitivity, and NPV than CSF Aβ1-42 but not Aβ42/40 ratio.
-
The contributors to persistent cognitive impairment and hippocampal atrophy in leucine-rich glioma-inactivated 1 antibody encephalitis (LGI1) patients are unknown.
-
After 20 years of follow-up, 123 patients (95%) were deceased.
-
Abeta (1-42/1-40) and GFAP independently associated with amyloid PET status (p = 0.009 and p < 0.001 respectively), and GFAP and NfL independently associated with syndrome diagnosis (p = 0.001 and p = 0.048 respectively).
-
The neuropathology of Parkinson's disease dementia (PDD) is heterogenous, and the impacts of each pathophysiology and their synergistic effects are not fully understood.
-
We compared regional retention of 18F-flortaucipir between 20 patients with Lewy body disorders (LBD), 12 Alzheimer's disease patients with positive amyloid positron emission tomography (PET) scans (AD+Aβ) and 15 healthy controls with negative amyloid PET scans (HC-Aβ).
-
Neurodegenerative diseases are a growing burden, and there is an urgent need for better biomarkers for diagnosis, prognosis, and treatment efficacy.
-
ANG levels didn't differ significantly between cases and controls.
-
Aβ1-42, tTau and pTau (but not Aβ1-40) and the ratios with Aβ1-42 had good diagnostic agreement with 18 F-Florbetapir PET.
-
Plasma NfL levels correlated with disease severity and progression in terms of both motor and cognitive functions in PD.
-
Plasma tau was higher in patients with AD than cognitively normal controls (P < .001, area under the receiver operating characteristic curve = 0.79) similarly to CSF tau and CSF P-tau and was negatively correlated with cognition in AD.
-
We found no disease effects on retinal vascular measures (all β's < |0.15|, all P > .2), adjusted for confounders.
-
A group of living former NFL players with cognitive and neuropsychiatric symptoms had higher tau levels measured by PET than controls in brain regions that are affected by CTE and did not have elevated amyloid-beta levels.
-
We investigated the effect of baseline Aβ, sex, and APOE on longitudinal tau accumulation in cerebrospinal fluid (CSF) in clinically normal older adults.
-
NFL discriminated patients from controls with an area under the curve of 0.914 (95% CI, 0.843-0.984; p < 0.001) (cut-off: 76.46 pg/mL; 94% sensitivity, 76.9% specificity).
-
50/100
Twenty-five/38 (65.8%) amyloid PET/CT scans resulted positive for amyloid deposition.
-
The forms of tau in CSF and plasma are distinct, but in each specimen type, the levels of certain fragments are increased in AD.
-
Among the hip fracture patients, 88.6% of the cognitively normal (Clinical Dementia Rating-CDR 0; n = 70) and 98.8% with mild cognitive impairment (CDR 0.5; n = 81) fell in the abnormal biomarker categories by the A/T/N classification.
-
Magnetic resonance-guided focused ultrasound in combination with intravenously injected microbubbles has been shown to transiently open the blood-brain barrier, and reduce beta-amyloid and tau pathology in animal models of Alzheimer's disease.
-
CSF biomarkers and amyloid positron emission tomography reflect different aspects of Alzheimer's disease brain pathology, and therefore, less-than-perfect correspondence is expected.
-
50/100
WMH volume within the inferior fronto-occipital fasciculus (IFOF) was the highest among all tract ROIs and associated with reduced FC in IFOF-connected DMN areas, independently of global AV-45 PET.
-
CSF p/t-tau ratio and NfL levels are strongly driven by ALS status.
-
The PET Core has demonstrated a variety of methods for the standardization of biomarkers such as florbetapir PET in a multicenter setting.
-
ARIA-H represents a spectrum of MRI findings due to haemosiderin deposition that appears to be related to impaired vascular integrity.
From across this topic
10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- 4D flow MRI hemodynamic biomarkers for cerebrovascular diseases
- Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials
- Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions
- Longitudinal evaluation of the natural history of amyloid-β in plasma and brain
- Development and clinical validation of CT-based regional modified Centiloid method for amyloid PET
- Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer's disease
- Benchmarking of a multi-biomarker low-volume panel for Alzheimer's Disease and related dementia research
- Elecsys pT181p immunoassay: Clinical performance for ruling out amyloid pathology
- Soluble LR11 competes with amyloid β in binding to cerebrospinal fluid-high-density lipoprotein
- Diagnostic utility of plasma p-tau217 differs by Alzheimer's disease tau-based subtypes